TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02572570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtek Bulk Fill Posterior
Description: Tooth (teeth) affected by dental caries or with an existing defective filling restored using the materials listed (Filtek Bulk Fill Posterior). Procedures done using local anesthesia and following ordinary restorative techniques.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtek Supreme Ultra
Description: Tooth (teeth) affected by dental caries or with an existing defective filling restored using the materials listed (Filtek Supreme Ultra). Procedures done using local anesthesia and following ordinary restorative techniques.
Study: NCT04148586

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Breast Irradiation
Description: Whole Breast Irradiation after CBS in females with DCIS and early stage breast cancer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Breast Irradiation
Description: Whole Breast Irradiation after CBS in females with DCIS and early stage breast cancer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Breast Irradiation
Description: Whole Breast Irradiation after CBS in females with DCIS and early stage breast cancer
Study: NCT01215396

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: AminoVital Amino Acid formulation
Description: Contains minerals, vitamin C, flavour and sweetener.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino Vital Amino Acid formulation
Description: Contains minerals, vitamin C, flavour and sweetener and an amino acid mixture (2.4g of AA as: leucine, isoleucine, valine, arginine and glutamine).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino Vital Amino Acid formulation
Description: Contains minerals, vitamin C, flavour and sweetener and a double dose of the amino acid mixture (4.8 g of AA as: leucine, isoleucine, valine, arginine and glutamine).
Study: NCT03726970

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CBCT radiation
Description: CBCT scanning

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CBCT radiation
Description: CBCT scanning
Study: NCT00442897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin (+) ezetimibe
Description: simvastatin (+) ezetimibe 10/20mg, tablet, once daily, 12wks(sub group:24wks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: atorvastatin
Description: atorvastatin 10mg, tablet, once daily, 12wks(sub group:24wks)
Study: NCT01643577

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture for gastroparesis
Description: A series of acupuncture points selected for the treatment of gastroparesis will be used at each of the 10 acupuncture sessions

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture for musculoskeletal pain
Description: Acupuncture points selected for the treatment of musculoskeletal pain will be used during each of the 10 acupuncture sessions
Study: NCT04213885

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PXL 330 Platinum device/Riboflavin
Description: 30mW, 5 sec, 5 sec off, 10 minutes of illumination
Study: NCT00661674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO
Study: NCT02881476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological: Cell-based therapy
Description: Human allogeneic Wharton's jelly-derived mesenchymal stem cell transplantation in ALS patients.
Study: NCT04591418

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotary handpieces
Description: Dental Caries removal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: Dental Caries removal
Study: NCT01252628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866 (SCCHN)
Description: PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab (SCCHN)
Description: Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab (SCCHN)
Description: Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866 (CRC)
Description: PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab (CRC)
Description: Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab (CRC)
Description: Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.
Study: NCT03932487

Intervention type: OTHER
Intervention: urinary iodine and urine BPA
Description: urinary iodine and urine BPA

Intervention type: OTHER
Intervention: urinary iodine and urine BPA
Description: urinary iodine and urine BPA
Study: NCT02888769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). Non-smokers will receive two general messages, two hypertension messages, one medication adherence message and one physical activity message per week. Smokers will receive one general message, two hypertension messages, one medication adherence message, one physical activity message and one smoking cessation message per week. Prior to study commencement, a bank of 280 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
Study: NCT03986749

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Doppler ultrasonography after bursa augmentation
Description: Dynamic ultrasound examination with Grading of blood vessels using the modified Ohberg Score in the longitudinal scan in dynamic ultrasound of the rotator cuff tendon - primary to surgery and 3 weeks later.
Study: NCT02109133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deep neuromuscular blockade
Description: deep neuromuscular blockade using rocuronium and reverse with sugammadex

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: moderate neuromuscular blockade
Description: moderate neuromuscular blockade using atracurium and reverse with neostigmine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Study: NCT00373685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: open-label

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Any commercially available NSAID with the indication for osteoarthritis
Description: dosing as per USPI label related to the chosen commercially marketed NSAID
Study: NCT02125578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB017 (PEGylated Interferon Beta-1a)
Description: Each participant will receive BIIB017 every other week or every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB017 (PEGylated Interferon Beta-1a)
Description: Each participant will receive BIIB017 every other week or every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB017 (PEGylated Interferon Beta-1a)
Description: Each participant will receive BIIB017 every other week or every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Each participant will receive placebo every other week or every 4 weeks.
Study: NCT01154153

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: 1 spray/nostril, once daily in the morning, for 8 to 24 days during the screening phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray
Description: 1 spray/nostril, once daily in the morning, for 8 to 24 days during the screening phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ)
Description: Treatment assignment was randomized with stratification by sex and age group (\>=2 to \<6, \>=6 to \<12 years old).~* For children who were \>=2 to \<6 years old, 1 spray/nostril (110 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.~* For children who were \>=6 yrs to \<12 years old, either 1 spray/nostril (110 µg TAA-AQ) or 2 sprays/nostril (220 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Treatment assignment was randomized with stratification by sex and age group (\>=2 to \<6, \>=6 to \<12 years old).~* For children who were \>=2 to \<6 years old, 1 spray/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.~* For children who were \>= 6 yrs to \<12 years old, either 1 spray/nostril or 2 sprays/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Claritin® Syrup
Description: Children's Claritin® Syrup \[5 mg of loratadine per 5 mL\] could be taken orally for the relief of AR symptoms throughout the study on an as needed basis, according to the Food and Drug Administration-approved manufacturer's label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Claritin® Syrup
Description: Children's Claritin® Syrup \[5 mg of loratadine per 5 mL\] could be taken orally for the relief of AR symptoms throughout the study on an as needed basis, according to the Food and Drug Administration-approved manufacturer's label.
Study: NCT00819650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Licartin (generic name,[131I]metuximab injection)
Description: Licartin, radioiodination of Metuximab with Na\[131I\],with radiochemical purity above 95% and specific activity between 173.25-288.75 MBq/ml.All patients in the treatment group received Licartin 3 times at an interval of 28 days beginning from the 4th week after liver resection
Study: NCT01566292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Botulinum Toxin type A, 200-300 UI dilued in 6 ml of saline solution
Study: NCT01724359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: The recommended Paliperidone extended-release (ER) dose will be 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily. Adjustment of the dosage will be done at the investigator's discretion.
Study: NCT04694040

Intervention type: DEVICE
Intervention: Modjaw® device
Description: Analysis of mandibular kinematics with Modjaw® device
Study: NCT03676023

Intervention type: DRUG
Intervention: Tranexamic Acid
Description: Inhalation of Transexamic acid in age adjusted dosing
Study: NCT03626610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise prehabilitation during chemotherapy before surgery
Description: Monitored exercise training in patients with a new diagnosis of oesophageal adenocarcinoma
Study: NCT02448628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150
Study: NCT01690065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib+AD induction
Description: • Post-remission consolidation chemotherapy~* 4 courses of high-dose cytarabine will be given as post-remission therapy. Cytarabine 3 g/m2 will be administered in a 3-hour iv infusion every 12 hours on days 1, 3, and 5 (a total of six doses per course).~* Nilotinib 400mg bid PO will be administered continuously during consolidation chemotherapy and for 2 years after the consolidation therapy or until allogeneic hematopoietic stem cell transplantation
Study: NCT02140489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amosartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amosartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amosartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Study: NCT02365051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care of Persons with Dementia in their Environments
Description: In-home visits by occupational therapist and advanced practice nurse.
Study: NCT02140489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amosartan and rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amosartan and rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amosartan and rosuvastatin
Study: NCT00683150

Intervention type: OTHER
Intervention: Endothelial Function Test
Description: Endothelial function tests performed within 20 days before surgery, when surgery begins (at the time of incision), every hour during surgery and then 1, 2, 3, and 5 days after surgery.
Study: NCT03505632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recruitment with low PEEP
Description: Volume controlled ventilation with TV 6-8 ml/PBW . RR adjusted to keep the EtCO2 35-40 mmHg. I/E ratio1:2 and FiO2 0.40.Patients will receive PEEP of 5cmH2O. RM will be done by increasing the PEEP in stepwise manner. First PEEP increase to 10 cmH2O (3 breaths),then to 15 cm H2O (3 breaths) and finally PEEP raise to 20 cmH2O (10 breaths).Then PEEP decrease by 5 cmH2O increments every (3 breaths) until back to PEEP 5 cmH2O. RM will take 2 minutes. RM will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40 cmH2O. Monitoring of the following parameters :Dynamic lung compliance ,Horowitz index ,dead space and driving pressure .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High PEEP without RM
Description: Volume controlled ventilation will carried out with tidal volume 6-8 ml/kg for predicted body weight. The PBW calculated according to the formula : 50 + 0.91 × {height (cm)-152.4} for men and 45.5 + 0.91 × {height (cm) - 152.4} for women. The respiratory rate adjusted to keep the EtCO2= 35-40 mmHg. The inspiratory to expiratory ratio (I:E ratio) 1:2 and FiO2 0.40.Patients will receive high PEEP of 15cmH2O from the start and continue all through the procedure . Monitoring of dynamic lung compliance,Horowitz index,dead space and driving pressure will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40cmH2O.
Study: NCT03223298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 37.5 units injected into each masseter muscle and 12.5 units into each temporalis muscle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: 1cc syringe
Study: NCT04494425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion
Study: NCT00424606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at the dose of 75 mg/m2 intravenously (IV) every 3 weeks for 4 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin at the dose of 90 mg/m2 IV every 3 weeks for 4 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
Study: NCT02758093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speed of Processing Training
Description: These are specific computerized exercises that are designed to increase the rate in which people can process visual information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speed of Processing Training
Description: These are specific computerized exercises that are designed to increase the rate in which people can process visual information.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Internet Navigational
Description: This is a sham condition in which participants will receive the same amount of social and computer contact as those randomized to receive the 10 hours of speed of processing training. In this condition, participants will learn how to do various activities on the internet.
Study: NCT03871400

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anterior cervical discectomy and fusion
Description: primary, 2-level, contiguous

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anterior cervical discectomy and fusion
Description: primary, 2-level, contiguous
Study: NCT04494425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Investigator's choice standard of care single agent chemotherapy; capecitabine tablets will be given orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Investigator's choice standard of care single agent chemotherapy; paclitaxel by intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Investigator's choice standard of care single agent chemotherapy; nab-paclitaxel by intravenous infusion
Study: NCT02579642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Low dose ketamine 0.2 mg/kg (or 0.5 mg/kg depending on results of interim analysis) administered with usual induction drugs for ECT
Study: NCT04586790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Oral Tablet
Description: midodrine group will receive midodrine 10 mg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral midodrine .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minirin oral tablet
Description: Minirin group will receive minirin 60 µg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral minirin .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nor-Adrenaline
Description: control group will receive IV nor-adrenaline and is gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .
Study: NCT04556669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous aPD-L1 armored anti-CD22 CAR T cells
Description: Autologous aPD-L1 armored CD22-targeting CAR T cells
Study: NCT02579642

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline administered with usual induction drugs for ECT
Study: NCT03089086

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed 4CMenB vaccine
Description: Two doses (0.5 mL each) of Bexsero ® vaccine at least 1 month to \<3 months apart in adolescents.
Study: NCT00920426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 30mg
Description: GSK1265744 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match GSK1265744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 5mg
Description: GSK1265744 5mg
Study: NCT05556408

Intervention type: DRUG
Group type: OTHER
Intervention: Succinylcholine
Description: 1.5mg/kg was given intravenously
Study: NCT02532777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone